文献速递心境障碍物质与行为成瘾

重性抑郁状态与致幻剂LSD使用趋势分析

Use of Lysergic Acid Diethylamide by Major Depression Status.
PubMed 文献 · JAMA Psychiatry · 2024-01-01

该调查分析2008至2019年美国18岁以上成人中过去一年非医疗使用LSD的流行趋势,按过去一年重性抑郁诊断分层。结果显示,抑郁成人LSD使用流行率从0.5%升至1.8%,非抑郁成人从0.2%升至0.8%,差异变化为0.8%,年轻及低收入抑郁人群增幅更明显。

要点

  • 抑郁成人LSD使用率增幅(1.3%)大于非抑郁成人(0.6%),差异变化0.8%。
  • 18-25岁抑郁成人LSD使用率增加3.3%,26-34岁增加2.7%。
  • 家庭年收入低于2万美元的抑郁成人LSD使用率增加1.9%。

核心结论

  • 2008至2019年美国抑郁成人过去一年LSD使用流行率增长幅度大于非抑郁成人。
  • 年轻成人和低收入抑郁人群的LSD使用增长尤为明显。

研究设计与样本

  • 调查研究,汇总2008至2019年美国全国药物使用与健康调查公开数据。

主要发现

  • 抑郁成人LSD使用率从2008年0.5%升至2019年1.8%,患病率差为1.3%(95%CI 1.0%-1.6%)。
  • 非抑郁成人LSD使用率从2008年0.2%升至2019年0.8%,患病率差为0.6%(95%CI 0.5%-0.7%)。
  • 抑郁与非抑郁成人LSD使用率变化的差异为0.8%(95%CI 0.5%-1.1%)。
  • 18-25岁抑郁成人患病率差为3.3%(95%CI 2.5%-4.2%),26-34岁为2.7%(95%CI 1.6%-3.8%)。
  • 家庭收入低于2万美元的抑郁成人患病率差为1.9%(95%CI 1.3%-2.6%)。

关键数值与推荐

  • 过去一年重性抑郁诊断依据DSM-IV标准。
  • 采用logistic回归模型分析LSD使用时间趋势,并校正社会人口学特征。
  • 加权访谈应答率在研究期间为64.9%至75.6%。

临床怎么用

  • 对报告使用LSD的抑郁患者,临床医生应讨论在医疗监督之外减少伤害和最大化获益的策略。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Renewed interest in the clinical potential of hallucinogens may lead people with depression to a generally more positive view of the use of lysergic acid diethylamide (LSD). Therefore, past-year LSD use among people with depression may be increasing in prevalence. OBJECTIVE: To assess time trends in the prevalence of past-year nonmedical LSD use by past-year major depression status and the variation in this association by sociodemographic characteristics. DESIGN, SETTING, AND PARTICIPANTS: This survey study used pooled publicly available data from 478 492 adults aged 18 years or older who were administered the National Survey on Drug Use and Health from 2008 through 2019. Statistical analysis was conducted from December 2022 to June 2023. MAIN OUTCOME AND MEASURES: Past-year major depression diagnoses per criteria from the DSM-IV were analyzed. Logistic regression models examined whether time trends in past-year nonmedical LSD use differed between adults with vs without past-year depression, adjusting for sociodemographic characteristics. Secondary analyses examined whether the trends in LSD use by depression status differed between sociodemographic subgroups. RESULTS: The analytic sample included 478 492 adults, of whom 51.8% were female, 56.1% were younger than 50 years, 11.7% were Black, 15.1% were Hispanic, 65.8% were White, and 7.5% were another race. Weighted interview response rates ranged from 64.9% to 75.6% during the study time frame. From 2008 to 2019, past-year use of LSD increased significantly more among adults with major depression (2008 prevalence, 0.5%; 2019 prevalence, 1.8%; prevalence difference [PD], 1.3% [95% CI, 1.0%-1.6%]) compared with adults without major depression (2008 prevalence, 0.2%; 2019 prevalence, 0.8%; PD, 0.6% [95% CI, 0.5%-0.7%]) (difference in difference, 0.8% [95% CI, 0.5%-1.1%]). This difference was particularly pronounced among young adults aged 34 years or younger (PD among those aged 18-25 years with depression, 3.3% [95% CI, 2.5%-4.2%]; PD among those aged 26-34 years with depression, 2.7% [95% CI, 1.6%-3.8%]) and individuals with incomes less than $75 000 per year (PD among those with income <$20 000, 1.9% [95% CI, 1.3%-2.6%]; PD among those with income $20 000-$49 999, 1.5% [95% CI, 1.0%-2.1%]; PD among those with income $50 000-$74 999, 1.3% [95% CI, 0.7%-2.0%]). CONCLUSIONS AND RELEVANCE: This study suggests that, from 2008 to 2019, there was a disproportionate increase in the prevalence of past-year LSD use among US adults with past-year depression. Among those with depression, this increase was particularly strong among younger adults and those with lower household incomes. Among individuals with depression who also report LSD use, clinicians should discuss potential strategies for mitigating harm and maximizing benefits in medically unsupervised settings.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Walsh CA, Gorfinkel L, Shmulewitz D, et al. Use of Lysergic Acid Diethylamide by Major Depression Status. JAMA Psychiatry. 2024. PMID: 37819655. doi:10.1001/jamapsychiatry.2023.3867

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。